IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer
Abstract Background Pancreatic cancer is characterized by a highly immunosuppressive tumor microenvironment and evasion of immune surveillance. Although programmed cell death 1 receptor (PD-1) blockade has achieved certain success in immunogenic cancers, the responses to the PD-1 antibody are not ef...
Main Authors: | Guoping Ding, Tao Shen, Chen Yan, Mingjie Zhang, Zhengrong Wu, Liping Cao |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-11-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-019-6145-8 |
Similar Items
-
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
by: Xin Wang, et al.
Published: (2019-02-01) -
PD-1 Blockade with Nivolumab as a New Immunotherapy for Classical Hodgkin’s Lymphoma
by: EA Demina
Published: (2018-07-01) -
Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
by: Funakoshi, Y., et al.
Published: (2022) -
CTLA-4 and PD-1 pathway Blockade : Combinations in the Clinic
by: Margaret Kathleen Callahan, et al.
Published: (2015-01-01) -
Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD‐L1
by: Kazuya Tsubouchi, et al.
Published: (2020-04-01)